JP2017529365A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529365A5
JP2017529365A5 JP2017515823A JP2017515823A JP2017529365A5 JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5 JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5
Authority
JP
Japan
Prior art keywords
alkyl
het
halo
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071349 external-priority patent/WO2016042089A1/en
Publication of JP2017529365A publication Critical patent/JP2017529365A/ja
Publication of JP2017529365A5 publication Critical patent/JP2017529365A5/ja
Pending legal-status Critical Current

Links

JP2017515823A 2014-09-17 2015-09-17 大環状lrrk2キナーゼ阻害剤 Pending JP2017529365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14290279.0 2014-09-17
EP14290279 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017529365A JP2017529365A (ja) 2017-10-05
JP2017529365A5 true JP2017529365A5 (enExample) 2018-09-13

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515823A Pending JP2017529365A (ja) 2014-09-17 2015-09-17 大環状lrrk2キナーゼ阻害剤

Country Status (20)

Country Link
US (1) US10377772B2 (enExample)
EP (1) EP3194405B1 (enExample)
JP (1) JP2017529365A (enExample)
KR (1) KR20170048599A (enExample)
CN (1) CN107108641A (enExample)
AU (1) AU2015316801B2 (enExample)
BR (1) BR112017005299A2 (enExample)
CA (1) CA2960777A1 (enExample)
DK (1) DK3194405T3 (enExample)
EA (1) EA032838B1 (enExample)
ES (1) ES2717510T3 (enExample)
HU (1) HUE043972T2 (enExample)
IL (1) IL251054B (enExample)
MX (1) MX2017003470A (enExample)
PL (1) PL3194405T4 (enExample)
SG (1) SG11201701936WA (enExample)
TR (1) TR201904514T4 (enExample)
TW (1) TW201625639A (enExample)
WO (1) WO2016042089A1 (enExample)
ZA (1) ZA201701841B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
AR124556A1 (es) * 2020-01-31 2023-04-12 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CR20220561A (es) 2020-05-06 2023-02-17 Servier Lab Nuevos inhibidores macrocíclicos de la quinasa de lrrk2
MX2023010910A (es) 2021-03-18 2023-09-27 Servier Lab Nuevos inhibidores macrociclicos de la quinasa de lrrk2.
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
AR130483A1 (es) 2022-09-15 2024-12-11 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132486A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132487A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132488A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
RU2170082C2 (ru) 1993-10-01 2001-07-10 Астра Актиеболаг Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CN1274690C (zh) 2000-12-28 2006-09-13 小野药品工业株式会社 三杂环化合物和包括其作为活性组分的药物
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
ES2393926T3 (es) 2004-10-21 2013-01-02 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gen KASPP (LRRK2), su producción y uso para la detección y tratamiento de trastornos neurodegenerativos
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
CN101365703B (zh) 2005-11-16 2013-11-06 S*Bio私人有限公司 杂烷基连接的嘧啶衍生物
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
ES2512727T3 (es) 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
SMT201700372T1 (it) * 2010-05-20 2017-09-07 Array Biopharma Inc Composti macrociclici come inibitori di trk chinasi
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
HUE027318T2 (en) * 2011-09-30 2016-10-28 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
PL2760453T3 (pl) 2011-09-30 2016-11-30 Makrocykliczne Inhibitory kinazy LRRK2

Similar Documents

Publication Publication Date Title
JP2017529365A5 (enExample)
JP2016506958A5 (enExample)
JP2019536785A5 (enExample)
JP2016506369A5 (enExample)
JP2016510797A5 (enExample)
JP2015509535A5 (enExample)
JP2020502092A5 (enExample)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
JP2012511588A5 (enExample)
JP2015514808A5 (enExample)
JP2016525135A5 (enExample)
JP2015531773A5 (enExample)
JP2018519343A5 (enExample)
JP2016510796A5 (enExample)
JP2016525136A5 (enExample)
JP2016507581A5 (enExample)
JP2013532652A5 (enExample)
JP2015504091A5 (enExample)
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
JP2017501237A5 (enExample)
JP2016531868A5 (enExample)
JP2019532067A5 (enExample)